Will Revlimid be covered by health insurance?

Will myeloma patients be able to get cheaper and better drugs this year? Now all eyes are on the Health Insurance Review and Assessment Service (HIRA) committee's decision on the reimbursement of Revlimid, a new drug for the disease, at the end of this month.

So far, the HIRA has barred reimbursement for Revlimid to treat myeloma, claiming that Celgene, the developer of Revlimid, should furt...